[Close correlations between CD20 expression, a small mature plasma cell morphology and t(11 ; 14) in multiple myeloma].
Stratification of patients with multiple myeloma (MM) may be important. We investigated 138 MM patients, focusing on correlations between CD20 expression, 11 ; 14 translocation, morphology of MM cells, cyclin D1 immunostaining, and the prognosis. About 15% of patients (7/47cases) were CD20-positive, small mature MM cells, with positive cyclin D1 in the nucleus and 11; 14 translocation. Two color analysis of CD38 x CD20 antigens may be necessary to investigate CD20 expression on MM cells. Rituximab may be effective for the treatment of CD20-positive MM.
Matsuda
Isao
I
Department of Hematology, Japanese Red Cross Medical Center.
Mori
Yuki
Y
Nakagawa
Yasunori
Y
Sawanobori
Masakazu
M
Uemura
Naoki
N
Suzuki
Kenshi
K
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000032:analysis*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics; D019938:Cyclin D1 / Q000032:analysis; D005260:Female; D015870:Gene Expression; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology / Q000473:pathology*; D010950:Plasma Cells / Q000473:pathology*; D011379:Prognosis; D000069283:Rituximab; D014178:Translocation, Genetic / Q000235:genetics*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D019938:Cyclin D1; D000069283:Rituximab